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OBJECTIVE—Circulating levels of soluble receptor for advanced
glycation end products (sRAGE) likely comprise both a secreted
isoform (esRAGE) and wild-type RAGE cleaved from the cell
membrane. Both sRAGE and esRAGE have been proposed as
biomarkers of cardiovascular disease (CVD), but prospective data
are limited. We examined the relationship of sRAGE and esRAGE
to incident coronary heart disease (CHD) and stroke in type 2
diabetic patients followed for 3.9 years in a trial of atorvastatin:
the Collaborative Atorvastatin Diabetes Study (CARDS).
RESEARCHDESIGN ANDMETHODS—We used a nested case-
control design sampling all incident cases of CVD with available
plasma and randomly selecting three control subjects, who were
free of CVD throughout follow-up, per case. Analysis was by Cox
regression with adjustment for treatment allocation and relevant
covariates.
RESULTS—sRAGE and esRAGE were strongly correlated (r =
0.88) and were both higher in those with lower BMI (P , 0.001),
higher adiponectin (P , 0.001), lower estimated glomerular ﬁl-
tration rate (P = 0.009), and white ethnicity (P , 0.001). Both
sRAGE and esRAGE were associated with incident CHD events,
independently of treatment allocation and the above factors; haz-
ard ratio (HR) = 1.74 (95% CI 1.25–2.41; P = 0.002) for a doubling
of the sRAGE level; HR = 1.45 (1.11–1.89; P = 0.006) for a doubling
of the esRAGE level. There was no signiﬁcant association with
stroke; HR for sRAGE = 0.66 (0.38–1.14). Atorvastatin, 10 mg
daily, did not alter sRAGE.
CONCLUSIONS—Higher levels of sRAGE and esRAGE are
associated with incident CHD but not stroke in type 2 diabetes.
Diabetes 60:2379–2385, 2011
Receptor for advanced glycation end products(RAGE) is a cell-surface molecule that bindsmany ligands, including advanced glycation endproducts (AGEs) (1,2). This binding results in
diverse responses, including altered gene expression and
cell migration and proliferation, in pathways that are con-
sidered to play a pivotal role in the pathogenesis of ath-
erosclerosis, heart failure, and other diabetes complications.
The involved pathways relevant to atherosclerosis are di-
verse; for example, blocking ligand binding to RAGE in
mice reduced diabetes-induced inﬂammation and athero-
sclerotic plaque formation and reduced vascular smooth
muscle proliferation and migration and extracellular matrix
production in response to injury (3). A circulating soluble
form of RAGE has been proposed as a potentially useful
biomarker of cardiovascular disease (CVD) in diabetes.
This soluble RAGE (total sRAGE) likely comprises both
the extracellular domain of wild-type, full-length RAGE,
which results from proteolytic cleavage at the cell surface,
and an endogenous secreted isoform lacking a trans-
membrane domain (RAGE-V1 or esRAGE) that can also be
measured separately (4–6). RAGE antagonists are in clinical
development as therapeutics for diabetes complications and
Alzheimer disease. An important question, therefore, is the
usefulness of circulating total sRAGE (hereafter termed
sRAGE) and esRAGE as potential biomarkers of diabetes
complications and need for therapy.
The published literature on esRAGE and sRAGE pre-
diction of complications in patients with diabetes is sparse
and conﬂicting (6–8). sRAGE levels have been found to be
higher in coronary disease cases, or those with higher ath-
erosclerotic burden, than control subjects in some studies
(7–12) but lower in others (13). esRAGE levels have been
mostly reported to be lower in case subjects, or those
with greater atherosclerosis burden, than control subjects
(11,14–16). However prospective data are essential to fully
understand the relationship between sRAGE and CVD. Two
recent prospective studies showed that higher levels of
sRAGE were associated with CVD in type 1 diabetes (8,12).
There are no prospective studies that have examined
both esRAGE and sRAGE as predictors of CVD in type 2
diabetes with adjustment for other risk factors. There is
also need for more clinical data on the relationship of
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circulating esRAGE and sRAGE with other factors in di-
abetes.
The primary purpose of this analysis was to examine the
relationship of serum esRAGE and sRAGE to incident
cardiovascular events. We also explored the relationship
of esRAGE and sRAGE with each other and with other risk
factors in type 2 diabetes. We examined these questions
using samples and data from a randomized controlled clin-
ical trial of statin therapy in type 2 diabetic patients without
prior CVD (the Collaborative Atorvastatin Diabetes Study
[CARDS]) (17).
RESEARCH DESIGN AND METHODS
The design of the CARDS trial has been reported previously (17). The trial was
conducted in 132 clinical centers in the U.K. and Ireland. In it, 2,838 patients
with type 2 diabetes without previous CVD were randomized to receive either
atorvastatin (10 mg daily) or placebo. Patients were ineligible if they had any
past history of myocardial infarction, angina, coronary vascular surgery, ce-
rebrovascular accident, or severe peripheral vascular disease. We checked
eligibility against the patients’ clinical notes. The median follow-up duration in
the trial was 3.9 years. The primary end point was major CVD events com-
prising myocardial infarction including silent infarction, unstable angina, acute
coronary heart disease (CHD) death, resuscitated cardiac arrest, coronary
revascularization procedures, or stroke. An independent end point committee
reviewed all reported cardiovascular events and deaths and classiﬁed them
according to criteria speciﬁed in the end point protocol. We used a nested case-
control design sampling all those incident cases of CVD (n = 210) during
follow-up in CARDS in whom a valid baseline prerandomization serum sample
was available and randomly selecting three control subjects per case subject
from those who completed the trial without a CVD event, stratiﬁed by treat-
ment allocation. A valid sample for sRAGE and esRAGE was ﬁnally available
in 167 (80%) of all cases, and the control subjects with sRAGE data (551)
comprised 20% of all those without CVD during follow-up.
Using prerandomization samples, serum sRAGE was measured using the
R&D Systems Quantikine Immunoassay (Minneapolis, MN) that is speciﬁc
for the extracellular domain of human RAGE. The assay coefﬁcient of varia-
tion was 4.4%. esRAGE was measured using the B-Bridge ELISA (B-Bridge
International, Cupertino, CA). This assay speciﬁcally measures the esRAGE/
RAGEv1 protein only due to the use of an antibody directed against the unique
COOH-terminal sequence of RAGE-v1 and does not cross-react with other
potential forms of sRAGE. The coefﬁcient of variation was 6%. The correct
terminology for this splice variant is RAGE-v1(6) but we retain the term
esRAGE here as that is how the assay is described by the manufacturers.
Sufﬁcient sample was available for sRAGE and esRAGE measurement for 715
and 780 participants, respectively. As these two assay systems for esRAGE
and sRAGE are constituted by individual antibodies and different standard
proteins, they are not directly comparable. Nonetheless, some information
can be gained by examining determinants of their relative amounts. To evaluate
whether atorvastatin affects sRAGE we also measured sRAGE in a posttreat-
ment sample taken at 1 year of follow-up. We did not measure esRAGE at
follow-up.
Statistical analysis usedmultiple linear regression with covariate adjustment
to examine cross-sectional determinants of sRAGE and esRAGE at baseline.
Analysis of prediction of CVD events was by Cox regression with adjustment for
treatment allocation and relevant covariates. The validity of the proportional
hazards assumption was conﬁrmed by a test for interaction of the hazard ratio
(HR) with time. Given the skewed distribution of sRAGE and esRAGE (see
Fig. 2), these were log transformed in the analysis. Analyses were conducted
using STATA 10 MP for Linux.
RESULTS
Table 1 shows the baseline characteristics of those study
participants with available baseline sRAGE data who went
on to become CVD cases compared with the control group
selected who did not develop CVD. Those who developed
CVD were older, were more likely be a current or ex-smoker,
had albuminuria, were male, and had slightly higher LDL-C.
Further analyses for CVD risk adjusted for these factors.
Among the 167 CVD cases, there were 128 CHD and 44
stroke events (5 people having both). Similar differences in
baseline characteristics were seen for CHD cases versus
control subjects as for CVD cases versus control subjects.
Figure 1 summarizes the main relationships we found
between other factors and sRAGE. A very similar pattern
of relationships was found for esRAGE. Neither sRAGE
nor esRAGE differed signiﬁcantly with age or by sex.
However, although the numbers of nonwhite participants
was low (n = 20 African Caribbean; n = 25 South Asians),
there were marked ethnic differences, with much lower
TABLE 1
Baseline characteristics of incident CVD cases and control subjects
CVD cases (n = 167) Control subjects (n = 551) P value for difference*
Mean (SE)
Age (years) 64 (0.53) 61 (0.34) ,0.001
BMI (kg/m2) 28.9 (0.25) 28.8 (0.15) 0.06
Systolic BP (mmHg) 146 (1.20) 144 (0.68) 0.63
LDL-C (mmol/L) 3.2 (0.06) 3.0 (0.03) 0.004
HDL-C (mmol/L) 1.37 (0.02) 1.4 (0.01) 0.52
HbA1c (%) 7.9 (0.10) 7.8 (0.06) 0.23
Median (interquartile range)
sRAGE (pg/mL) 1,404 (1,097–1,877) 1,404 (1,057–1,777) 0.096
Median esRAGE (pg/mL) 330 (240–460) 330 (240–430) 0.39
Diabetes duration (years) 8 (4–12) 6 (3–11) 0.25
Percentages
eGFR ,60 mL/min/1.73 m2 31 32 0.75
Men (%) 86 67 ,0.001
Current smoker (%) 28 23 0.02
White (%) 93 93 0.49
Albuminuria (%) 17 10 0.039
Retinopathy (%) 41 27 0.003
Metformin (%) 46 46 0.29
Insulin (%) 17 20 0.53
RAS drugs (%) 40 48 0.08
RAS, renin angiotensinogen system. *P values are for association of variables with CVD using logistic regression. Other than for age and sex,
the logistic model adjusted for age, sex, and treatment allocation.
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sRAGE and esRAGE in those of African Caribbean origin
compared with whites and South Asians having intermediate
levels. Those with lower estimated glomerular ﬁltration
rate (eGFR) had higher sRAGE and esRAGE but there was
no association with albuminuria (the prevalence of albu-
minuria in this study population was low, however [see
Table 1]). There was a slight inverse association between
HbA1c and esRAGE (Spearman r = 210; P = 0.006) but not
sRAGE (Spearman r = 20.06; P = 0.09). Those with lower
BMI levels had higher levels of both sRAGE and esRAGE,
and consistent with this, there was a positive correlation
with adiponectin (Spearman r = 0.14; P = 0.006). In a linear
regression model with the above variables considered si-
multaneously, sRAGE remained associated with BMI (P =
0.007) or adiponectin (P , 0.001), ethnicity (P = 0.002), and
eGFR level (P = 0.004). esRAGE remained associated with
BMI (P , 0.001) or adiponectin (P , 0.001), ethnicity (P ,
0.001), HbA1c (P = 0.019), and eGFR (P = 0.05). However,
together these factors explained no more than 6 and 10% of
the variance in sRAGE and esRAGE, respectively. There
was no signiﬁcant association between esRAGE and
smoking, lipids, blood pressure, antihypertensive agents,
diabetes duration, insulin, or oral diabetes drugs (data not
shown). Neither was there any association with high-
sensitivity C-reactive protein (Spearman r =20.02; P = 0.6).
We explored the relationship of sRAGE to esRAGE.
sRAGE and esRAGE were strongly correlated (Spearman
r = 0.88), with a median ratio of sRAGE to esRAGE levels
of 4.2 (ranging from threefold at the bottom 5% to sixfold
at the top 5%). When we explored whether associations of
patient characteristics to the ratio of sRAGE:esRAGE
existed, we found that a higher ratio was associated with
younger age (P = 0.001), higher HbA1c (P = 0.01), being
nonwhite (P = 0.003), and having a higher BMI (P = 0.002).
(P values shown are for a model including these charac-
teristics and sex simultaneously.)
We examined the relationship of sRAGE and esRAGE to
cardiovascular events. As shown in Table 1, there was no
apparent difference in esRAGE or sRAGE between cases
and control subjects for CVD. This lack of association was
conﬁrmed in a Cox regression model adjusting for age,
sex, and treatment (HR for sRAGE = 1.26; 95% CI 0.97–
1.64; P = 0.08). However for CHD considered separately,
both sRAGE and esRAGE were higher in cases than con-
trol subjects adjusted for age and sex. The median (inter-
quartile range) sRAGE was 1,499 pg/mL (1,138–1,910) in
cases and 1,395 pg/mL (1,046–1,777) in control subjects,
and the median esRAGE was 340 pg/mL (250–460) in cases
and 320 pg/mL (240–430) in control subjects. As shown in
Table 2 and Fig. 2 this association of both sRAGE and
esRAGE with CHD incidence was statistically signiﬁcant,
adjusted for age, sex, and treatment allocation (P = 0.003
for sRAGE and P = 0.023 for esRAGE; Table 2). In a Cox
regression model adjusting further for potential CHD risk
FIG. 1. Association of sRAGE with eGFR, BMI, and ethnicity. (A high-quality color representation of this ﬁgure is available in the online issue.)
TABLE 2
Association of sRAGE and esRAGE with CHD and stroke with
adjustment for other factors
CHD (N events = 128) Stroke (N events = 144)
Model HR* P value HR P value
1† sRAGE 1.57 (1.17–2.11) 0.003 0.77 (0.47–1.28) 0.31
esRAGE 1.36 (1.04–1.77) 0.023 0.88 (0.55–1.24) 0.35
2‡ sRAGE 1.66 (1.20–2.30) 0.002 0.67 (0.39–1.15) 0.15
esRAGE 1.43 (1.10–1.87) 0.008 0.85 (0.55–1.31) 0.46
3§ sRAGE 1.74 (1.25–2.41) 0.002 0.63 (0.37–1.09) 0.1
esRAGE 1.45 (1.11–1.89) 0.006 0.81 (0.52–1.24) 0.33
*Effect sizes are for a doubling of sRAGE/esRAGE. †Model 1 adjusts
for age, sex, and treatment group. ‡Model 2 extends model 1 by also
adjusting for lipids, BMI, ethnicity, smoking, SBP, diabetes duration, and
HbA1c. §Model 3 further adjusts for baseline eGFR and albuminuria.
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factors associated with baseline sRAGE and/or esRAGE,
the association was independent of other factors. As shown
in Table 2, model 3 adjusted for eGFR and albuminuria
status, but this had very little effect on the relationship of
sRAGE or esRAGE with CHD. There was no signiﬁcant
association between ethnicity and CHD (HR for white vs.
nonwhite = 0.6; P = 0.1), and adjusting for ethnicity did not
alter the association of esRAGE or sRAGE with CHD
(model 2). Restricting the analysis to whites only showed
similar effects (for example for model 1, the HR of CHD for
sRAGE restricted to whites was 1.58; P = 0.004). There
were too few nonwhites (n = 50) to model CVD events in
these participants separately. Adjusting for BMI slightly
strengthened the association of both sRAGE and esRAGE
with CHD (model 2). The relationship of esRAGE to CHD
was slightly weaker than the association of sRAGE with
CHD (P = 0.001; difference in log likelihood for the two
models = 22). In these models, esRAGE and sRAGE were
log2 transformed because of their skewed distribution.
Thus the HRs show the effect of a doubling of the sRAGE
or esRAGE level. The data were consistent with a linear
relationship of sRAGE with CHD. The HR for the mid-tertile
adjusted for age, BMI, and ethnicity was slightly elevated
at 1.11 (0.7–1.75) and for the top tertile was 1.62 (1.06–2.5),
with the P value for linear trend across tertiles being 0.025.
Using a logistic regression model, the same conclusions
were reached.
Also shown in Table 2, the HRs for the association of
sRAGE or esRAGE with stroke were in the opposite di-
rection to that for CHD but were not statistically signiﬁcant,
and the CIs are wide, consistent with the small number of
stroke events (n = 44).
We examined the effect of atorvastatin on sRAGE. As
shown in Fig. 3, sRAGE levels were very stable in both
treatment arms between baseline and 1-year follow-up.
Using samples from 469 people (n = 285 allocated placebo
and 184 allocated atorvastatin) who had prerandomization
and 1-year postrandomization samples available for sRAGE,
there was no effect of atorvastatin (10 mg daily) on within-
person change in sRAGE (b for treatment allocation =23.5;
95% CI 287 to 81, P = 0.9) in a regression model of follow-
up RAGE adjusted for baseline sRAGE, age, and sex. Given
the lack of atorvastatin effect on sRAGE and the strong
correlation between esRAGE and sRAGE at baseline, quan-
tiﬁcation of follow-up esRAGE was not considered worth-
while.
DISCUSSION
These data are novel and important in demonstrating that
both higher sRAGE and higher esRAGE levels predict fu-
ture CHD events in type 2 diabetes in a prospective study.
Our ﬁndings add in an important way to the literature on
sRAGE and vascular events in type 2 diabetes. To date, as
thoroughly reviewed by Kalea et al. (2), most of the studies
examining this question have been very small; few have
involved adjusting for a wide range of factors, and most
have been either cross-sectional studies of sRAGE with
atheroma burden (13,14), prospective intima-media thick-
ness or angiography studies (16,18), or case-control stud-
ies of existing cases of CVD (9). Perhaps not surprisingly,
given this, the literature is conﬂicting. Of note, to our
knowledge, no previous studies have measured both cir-
culating sRAGE and esRAGE in the same type 2 diabetic
subjects followed prospectively for vascular events. In the
ﬁrst prospective study of sRAGE and 85 incident cardio-
vascular events in type 1 diabetes, higher levels of sRAGE
were associated with incident vascular events, as in our
study. The study showed those in the middle and third
tertiles of sRAGE had HRs of 1.33 and 1.78, respectively
(8). Stroke was not examined separately in that study. In
our analysis, although being in the mid-tertile for sRAGE
was not signiﬁcantly associated with CHD, considered
separately, the HR for the mid-tertile was 1.11 with a sig-
niﬁcant linear trend, consistent with a continuous rather
than threshold effect of sRAGE on CHD. In the previous
report of sRAGE and CVD in type 1 diabetes, this contin-
uous nature of the relationship of sRAGE with events was
more apparent. We have reported the association of future
CHD events with sRAGE and esRAGE measured at just
a single time point. Although the correlation between
sRAGE at baseline and at 1 year follow-up was very high,
suggesting that this is a highly stable marker, it would
nonetheless be of interest to know whether the average of
FIG. 2. CHD incidence by tertile of sRAGE adjusted for age, sex, treatment group, lipids, BMI, ethnicity, smoking, SBP, diabetes duration, HbA1c,
baseline eGFR, and albuminuria. (A high-quality color representation of this ﬁgure is available in the online issue.)
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several measurements would be more strongly associated
with CHD. Future studies should address how these markers
vary through time in relation to progression of vascular
disease.
The relationship with CHD was independent of the wide
range of other factors we considered, including eGFR.
There has been discussion over whether associations of
sRAGE with vascular events merely reﬂect a secondary
rise in sRAGE with declining eGFR rather than a causal
relationship. In our data, adjusting for baseline eGFR did
not explain the relationship with CHD. In contrast, in the
recent prospective study in type 1 diabetes, ;28% of the
relationship of sRAGE with vascular events was explained
by renal function in regression analyses. In that study, the
authors noted that even then the direction of causality
cannot be deciphered unequivocally and of course animal
studies are consistent with at least some effect of RAGE
signaling on renal disease (19,20).
Our study yields several other important novel pieces of
information about circulating sRAGE and esRAGE. First we
demonstrated that circulating serum sRAGE and esRAGE
levels are highly correlated in patients with diabetes. Con-
sistent with this, they share similar associations with other
risk factors. As reported in an earlier smaller study, we note
that, based on comparing the concentrations of circulating
esRAGE with sRAGE, most of the circulating sRAGE seems
to be from cleaved wild-type RAGE rather than esRAGE (5).
We also demonstrated that there are large differences in
sRAGE and esRAGE levels between ethnic groups with
lower sRAGE and esRAGE in those of African Caribbean
origin compared with whites, with South Asians having
intermediate levels. This is consistent with previous reports
of whites having higher levels than those of African or
Hispanic origin (21,22). We ensured that ethnicity was not
confounding the relationship between sRAGE and CHD
by adjusting for it in the modeling process and by con-
ﬁrming the association in a model restricted to whites. We
found that higher BMI is associated with lower sRAGE and
esRAGE, which is not what one might have expected if
higher levels of each are associated with CHD. However,
lower sRAGE was found associated with higher BMI in
nondiabetic subjects previously (23) and was associated
with metabolic syndrome (14) and some other inﬂammatory
states, such as rheumatoid arthritis (24). Whether these
lower levels of sRAGE relate to its role as a decoy for
RAGE ligands in such inﬂammatory states is unclear.
There was little correlation of sRAGE with glycemic con-
trol. The weak inverse association of HbA1c and esRAGE
levels suggests that exploration of whether factors related
to glycemia, possibly AGEs, alter splicing is of interest.
We conﬁrm that those with poorer renal function have
higher levels of sRAGE and esRAGE. However, it is note-
worthy that relatively little interindividual variation in sRAGE
or esRAGE levels is explained by the many patient char-
acteristics we examined (,10%). This and the ethnic dif-
ferences suggest strong genetic control of sRAGE and
esRAGE levels, consistent with emerging literature on
RAGE genetics (2). We also demonstrate in this large trial
that statin therapy has little effect on sRAGE levels, sup-
porting the importance of the development of speciﬁc
RAGE inhibitors. This is in conﬂict with some smaller
studies suggesting effects of statins (14,25).
There are many potential mechanisms through which
RAGE signaling may be related to vascular disease in di-
abetes (1,26). For both sRAGE and esRAGE, the existing
knowledge suggests possible opposing relationships of cir-
culating levels with vascular disease. For example, circu-
lating soluble RAGE may act as a decoy for other ligands
that bind to RAGE, thereby having an anti-atherosclerotic
effect; if this mechanism is dominant, then one would ex-
pect that higher sRAGE relates to fewer vascular events.
However, there is also emerging evidence that proteolytic
cleavage, through which the component of sRAGE that
does not derive from esRAGE (so-called cleaved RAGE) is
formed, is part of a regulatory process and may reﬂect
ongoing inﬂammation (4,5), in which case one would ex-
pect higher levels to be associated with more vascular
disease. It is also unclear whether elevated esRAGE levels
would predict more or less complications. Our analysis
shows that for CHD, the predominant relationship is a posi-
tive one, higher levels are associated with higher disease
incidence, and suggests that given current assays, circulat-
ing cleaved RAGE may be a more useful predictor of CHD
than esRAGE. Clearly if we had been able to assay cleaved
RAGE separately, this would have been valuable for testing
this latter point directly.
FIG. 3. Median (interquartile range) sRAGE at baseline and 1 year postrandomization by treatment group. (A high-quality color representation of
this ﬁgure is available in the online issue.)
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We found no signiﬁcant relationship with stroke, and in-
deed the HR was in the opposite direction to that for CHD.
However, the power for examining relationships with stroke
events was low with only 44 stroke events in this study. It
is possible that higher sRAGE levels may have a different
relationship with disease in the coronary vasculature than
in brain, perhaps reﬂecting increased inﬂammation-related
processes in coronary disease but being more a marker of
decreased RAGE ligand binding in brain. It is interesting
that, consistent with this, a recent study examining sub-
clinical stroke reported that higher sRAGE was associated
with fewer subclinical strokes (21). That there could be
different associations of sRAGE with disease in brain than
other tissues is also plausible given that proteolysis of
RAGE, which would lead to higher levels of sRAGE, has
been postulated to prevent Abeta peptide transport across
the blood–brain barrier and thereby b-amyloid deposition
(4). In turn, there is increasing evidence that the extent of
b-amyloid deposition can inﬂuence the degree of brain
injury with ischemic episodes and alter vascular function
in brain (27).
Of course we realize it is important to differentiate be-
tween steady-state circulating levels of wild-type sRAGE
and the cell-surface expression of sRAGE. Circulating levels
will presumably reﬂect both expression of RAGE and pro-
teolytic cleavage of RAGE and possibly other factors, and
these may differ in their importance for pathogenic effects.
The relationship between circulating levels of sRAGE and
expression levels of RAGE is likely to be complex (6).
Many splice variants of RAGE are not secreted (6). Thus,
our study of circulating serum levels focuses on sRAGE
and esRAGE more from the perspective of their potential
usefulness as biomarkers rather than inferring what is
happening with respect to RAGE expression or binding of
ligands to RAGE. A ﬁrst step in demonstrating potential
usefulness of biomarkers is the evidence of a prospective
relationship as demonstrated here, but detailed analysis of
the marginal predictive utility of sRAGE as a biomarker
and its role in net reclassiﬁcation improvement will require
a study with many more events, perhaps achieved through
meta-analysis.
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